Embla Medical hf. (CPH:EMBLA)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 12.70B |
| Revenue (ttm) | 5.91B |
| Net Income (ttm) | 530.09M |
| Shares Out | 427.49M |
| EPS (ttm) | 1.24 |
| PE Ratio | 23.92 |
| Forward PE | 19.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,806 |
| Average Volume | 59,057 |
| Open | 29.20 |
| Previous Close | 29.70 |
| Day's Range | 29.00 - 30.20 |
| 52-Week Range | 25.01 - 37.90 |
| Beta | 0.46 |
| RSI | 42.78 |
| Earnings Date | Feb 3, 2026 |
About Embla Medical
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides os... [Read more]
Financial Performance
In 2025, Embla Medical's revenue was $928.69 million, an increase of 8.63% compared to the previous year's $854.89 million. Earnings were $83.34 million, an increase of 22.05%.
Financial numbers in USD Financial StatementsNews
Embla Medical hf. (OSSUY) Q4 2025 Earnings Call Transcript
Embla Medical hf. (OSSUY) Q4 2025 Earnings Call Transcript
Embla Medical hf: Interim Report Q4 and Full Year 2025
COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full Year 2025 Sveinn Sölvason, President and CEO, comments: "We delivered solid sales in the fourth qua...
Embla Medical hf. (OSSUY) Q3 2025 Earnings Call Transcript
Embla Medical hf. (OTCPK:OSSUY) Q3 2025 Earnings Call October 21, 2025 3:00 AM EDT Company Participants Sveinn Sölvason - President & CEO Gudny Sveinsdottir - Chief Financial Officer Conference Call P...
Embla Medical hf: Interim Report Q3 2025
COPENHAGEN, Denmark , Oct. 21, 2025 /PRNewswire/ -- Announcement no. 49/2025 Interim report Q3 2025 21 October 2025 Sveinn Sölvason, President and CEO, comments: "Sales in Q3 2025 amounted to USD 237...
Embla Medical hf: Embla Medical closes the majority share investment in Streifeneder ortho.production GmbH
Announcement no. 39/2025 29 August 2025 Reference is made to announcement no.
Embla Medical hf: Interim Report Q2 2025
Announcement no. 33/2025 Interim report Q2 2025 22 July 2025 COPENHAGEN, Denmark , July 22, 2025 /PRNewswire/ -- Sveinn Sölvason, President and CEO, comments: "Sales in Q2 2025 amounted to USD 232 mil...
Embla Medical hf: Embla Medical signs agreement to invest in a majority share in Streifeneder ortho.production GmbH
Announcement no. 31/2025 17 July 2025 REYKJAVIK, Iceland and COPENHAGEN, Denmark , July 17, 2025 /PRNewswire/ -- Embla Medical (NASDAQ Copenhagen: EMBLA), a leading global provider of innovative mobil...
Embla Medical hf: Interim Report Q3 2024
Announcement no. 12/2024 Interim report Q3 2024 22 October 2024 COPENHAGEN, Denmark , Oct. 22, 2024 /PRNewswire/ -- Sveinn Sölvason, President and CEO, comments: "We delivered solid sales in the thir...
Embla Medical hf: Interim Report Q2 2024
COPENHAGEN, Denmark , July 23, 2024 /PRNewswire/ -- D elivering our highest ever quarterly sales amounting to USD 217 million Organic growth of 6% for Q2 driven strong performance in Prosthet...
Ukrainian medical professionals receive comprehensive training in the field of lower limb prosthetics: Össur
REYKJAVIK, Iceland , Oct. 16, 2023 /PRNewswire/ -- Össur (Nasdaq: OSSR), a leading global provider of innovative mobility solutions, recently conducted its first multi-disciplinary educational event f...